세계의 호르몬 불응성 전립선암 (HRPCA) 시장 2019 : 제조사별, 지역별, 종류/용도별, 시장예측

■ 영문 제목 : Global Hormone Refractory Prostate Cancer (HRPCA) Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

Globalinforesearch가 발행한 조사보고서이며, 코드는 GIR-AC0771 입니다.■ 상품코드 : GIR-AC0771
■ 조사/발행회사 : Globalinforesearch
■ 발행일 : 2019년 1월 16일
■ 페이지수 : 102
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일
■ 조사대상 지역 : 글로벌
■ 산업 분야 : 의약품, 의료
■ 판매가격 / 옵션 (부가세별도)
Single User (1명 열람용)USD3,480 ⇒환산₩4,176,000견적의뢰/주문/질문
Multi User (5명 열람용)USD5,220 ⇒환산₩6,264,000견적의뢰/주문/질문
Corporate User (동일기업내 공유가능)USD6,960 ⇒환산₩8,352,000견적의뢰/구입/질문
가격옵션 설명
- 지불하실 금액은 상기 원화금액에 부가세(10%)를 더한 금액입니다.
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제이며, 납품후 5일이내에 청구서를 발행/송부합니다.
본 조사보고서는 호르몬 불응성 전립선암 (HRPCA)의 세계시장에 대해서 조사분석한 자료로서, 호르몬 불응성 전립선암 (HRPCA)의 세계시장 개요, 시장동향, 종류/용도별 시장규모, 지역별 분석 (북미, 유럽, 아시아, 남미, 중동/아프리카), 관련기업 정보등이 포함되어 있습니다.
・세계의 호르몬 불응성 전립선암 (HRPCA)시장동향
・관련기업 개요 (사업개요, 제품종류, 판매동향, 시장점유율)
・주요 지역별 호르몬 불응성 전립선암 (HRPCA) 시장분석/시장규모
  - 북미시장 (미국, 캐나다, 멕시코)
  - 유럽시장 (독일, 영국, 프랑스, 러시아, 이탈리아)
  - 아시아시장 (중국, 일본, 한국, 인도, 동남아시아)
  - 남미시장 (브라질, 아르헨티나, 콜롬비아)
  - 중동/아프리카시장 (사우디아라비아, 터키, 이집트, 나이지리아, 남아프리카)
・호르몬 불응성 전립선암 (HRPCA)의 종류별 시장분석/시장규모
・호르몬 불응성 전립선암 (HRPCA)의 용도별 시장분석/시장규모
・호르몬 불응성 전립선암 (HRPCA)의 세계시장 예측 (지역별 예측, 종류별/용도별 시장예측)
・호르몬 불응성 전립선암 (HRPCA)의 판매채널, 유통업체 분석
...
■ 보고서 개요

Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.

Scope of the Report:
This report focuses on the Hormone Refractory Prostate Cancer (HRPCA) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Hormone Refractory Prostate Cancer (HRPCA) is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Surgery

Market Segment by Applications, can be divided into
Hospitals
Ambulatory Surgical Centers
Specialty Clinics

There are 15 Chapters to deeply display the global Hormone Refractory Prostate Cancer (HRPCA) market.
Chapter 1, to describe Hormone Refractory Prostate Cancer (HRPCA) Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Hormone Refractory Prostate Cancer (HRPCA), with sales, revenue, and price of Hormone Refractory Prostate Cancer (HRPCA), in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Hormone Refractory Prostate Cancer (HRPCA), for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Hormone Refractory Prostate Cancer (HRPCA) market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Hormone Refractory Prostate Cancer (HRPCA) sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

■ 보고서 목차

Table of Contents

1 Market Overview
1.1 Hormone Refractory Prostate Cancer (HRPCA) Introduction
1.2 Market Analysis by Type
1.2.1 Chemotherapy
1.2.2 Hormonal Therapy
1.2.3 Immunotherapy
1.2.4 Radiation Therapy
1.2.5 Surgery
1.3 Market Analysis by Applications
1.3.1 Hospitals
1.3.2 Ambulatory Surgical Centers
1.3.3 Specialty Clinics
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Astellas Inc
2.1.1 Business Overview
2.1.2 Hormone Refractory Prostate Cancer (HRPCA) Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Sanofi S.A
2.2.1 Business Overview
2.2.2 Hormone Refractory Prostate Cancer (HRPCA) Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Dendreon Corporation, Bayer AG
2.3.1 Business Overview
2.3.2 Hormone Refractory Prostate Cancer (HRPCA) Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Johnson & Johnson
2.4.1 Business Overview
2.4.2 Hormone Refractory Prostate Cancer (HRPCA) Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Hormone Refractory Prostate Cancer (HRPCA) Manufacturer Market Share in 2017
3.3.2 Top 6 Hormone Refractory Prostate Cancer (HRPCA) Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Hormone Refractory Prostate Cancer (HRPCA) Market Analysis by Regions
4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Market Share by Regions
4.1.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Regions (2013-2018)
4.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Regions (2013-2018)
4.2 North America Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
4.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
4.5 South America Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
5 North America Hormone Refractory Prostate Cancer (HRPCA) by Countries
5.1 North America Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Market Share by Countries
5.1.1 North America Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Countries (2013-2018)
5.1.2 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Countries (2013-2018)
5.2 United States Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
5.3 Canada Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
5.4 Mexico Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
6 Europe Hormone Refractory Prostate Cancer (HRPCA) by Countries
6.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Market Share by Countries
6.1.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Countries (2013-2018)
6.2 Germany Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
6.3 UK Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
6.4 France Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
6.5 Russia Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
6.6 Italy Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
7 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) by Countries
7.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Countries (2013-2018)
7.2 China Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
7.3 Japan Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
7.4 Korea Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
7.5 India Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
8 South America Hormone Refractory Prostate Cancer (HRPCA) by Countries
8.1 South America Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Market Share by Countries
8.1.1 South America Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Countries (2013-2018)
8.1.2 South America Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
8.3 Argentina Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
8.4 Colombia Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
9 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) by Countries
9.1 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
9.3 UAE Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
9.4 Egypt Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
9.5 Nigeria Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
9.6 South Africa Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
10 Global Hormone Refractory Prostate Cancer (HRPCA) Market Segment by Type
10.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales and Market Share by Type (2013-2018)
10.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue and Market Share by Type (2013-2018)
10.2 Chemotherapy Sales Growth and Price
10.2.1 Global Chemotherapy Sales Growth (2013-2018)
10.2.2 Global Chemotherapy Price (2013-2018)
10.3 Hormonal Therapy Sales Growth and Price
10.3.1 Global Hormonal Therapy Sales Growth (2013-2018)
10.3.2 Global Hormonal Therapy Price (2013-2018)
10.4 Immunotherapy Sales Growth and Price
10.4.1 Global Immunotherapy Sales Growth (2013-2018)
10.4.2 Global Immunotherapy Price (2013-2018)
10.5 Radiation Therapy Sales Growth and Price
10.5.1 Global Radiation Therapy Sales Growth (2013-2018)
10.5.2 Global Radiation Therapy Price (2013-2018)
10.6 Surgery Sales Growth and Price
10.6.1 Global Surgery Sales Growth (2013-2018)
10.6.2 Global Surgery Price (2013-2018)
11 Global Hormone Refractory Prostate Cancer (HRPCA) Market Segment by Application
11.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Ambulatory Surgical Centers Sales Growth (2013-2018)
11.4 Specialty Clinics Sales Growth (2013-2018)
12 Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
12.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Growth Rate (2018-2023)
12.2 Hormone Refractory Prostate Cancer (HRPCA) Market Forecast by Regions (2018-2023)
12.2.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
12.2.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
12.2.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
12.2.4 South America Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
12.2.5 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
12.3 Hormone Refractory Prostate Cancer (HRPCA) Market Forecast by Type (2018-2023)
12.3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Forecast by Type (2018-2023)
12.3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share Forecast by Type (2018-2023)
12.4 Hormone Refractory Prostate Cancer (HRPCA) Market Forecast by Application (2018-2023)
12.4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Sales Forecast by Application (2018-2023)
12.4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source

List of Tables and Figures

Figure Hormone Refractory Prostate Cancer (HRPCA) Picture
Table Product Specifications of Hormone Refractory Prostate Cancer (HRPCA)
Figure Global Sales Market Share of Hormone Refractory Prostate Cancer (HRPCA) by Types in 2017
Table Hormone Refractory Prostate Cancer (HRPCA) Types for Major Manufacturers
Figure Chemotherapy Picture
Figure Hormonal Therapy Picture
Figure Immunotherapy Picture
Figure Radiation Therapy Picture
Figure Surgery Picture
Figure Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Applications in 2017
Figure Hospitals Picture
Figure Ambulatory Surgical Centers Picture
Figure Specialty Clinics Picture
Figure United States Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure Canada Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure Mexico Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure Germany Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure France Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure UK Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure Russia Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure Italy Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure China Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure Japan Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure Korea Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure India Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure Brazil Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure Egypt Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure South Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Figure Nigeria Hormone Refractory Prostate Cancer (HRPCA) Revenue (Value) and Growth Rate (2013-2023)
Table Astellas Inc Basic Information, Manufacturing Base and Competitors
Table Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Type and Applications
Table Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Sanofi S.A Basic Information, Manufacturing Base and Competitors
Table Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Type and Applications
Table Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Dendreon Corporation, Bayer AG Basic Information, Manufacturing Base and Competitors
Table Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Type and Applications
Table Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Type and Applications
Table Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales by Manufacturer (2016-2017)
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Manufacturer in 2016
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Manufacturer in 2017
Table Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Manufacturer (2016-2017)
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Manufacturer in 2016
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Manufacturer in 2017
Figure Top 3 Hormone Refractory Prostate Cancer (HRPCA) Manufacturer (Revenue) Market Share in 2017
Figure Top 6 Hormone Refractory Prostate Cancer (HRPCA) Manufacturer (Revenue) Market Share in 2017
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2013-2018)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales by Regions (2013-2018)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Regions (2013-2018)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Regions (2013-2018)
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Regions in 2013
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Regions in 2017
Figure North America Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Europe Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure South America Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure North America Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2013-2018)
Table North America Hormone Refractory Prostate Cancer (HRPCA) Sales by Countries (2013-2018)
Table North America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries (2013-2018)
Figure North America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries in 2013
Figure North America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries in 2017
Table North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Countries (2013-2018)
Table North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2013-2018)
Figure North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries in 2013
Figure North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries in 2017
Figure United States Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Canada Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Mexico Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2013-2018)
Table Europe Hormone Refractory Prostate Cancer (HRPCA) Sales by Countries (2013-2018)
Table Europe Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries (2013-2018)
Table Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Countries (2013-2018)
Figure Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries in 2016
Figure Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries in 2017
Figure Germany Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure UK Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure France Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Russia Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Italy Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2013-2018)
Table Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales by Countries (2013-2018)
Table Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries (2013-2018)
Figure Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries 2017
Table Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Countries (2013-2018)
Figure Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries 2017
Figure China Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Japan Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Korea Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure India Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure South America Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2013-2018)
Table South America Hormone Refractory Prostate Cancer (HRPCA) Sales by Countries (2013-2018)
Table South America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries (2013-2018)
Figure South America Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries in 2017
Table South America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Countries (2013-2018)
Table South America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2013-2018)
Figure South America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries in 2017
Figure Brazil Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Argentina Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Colombia Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2013-2018)
Table Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales by Countries (2013-2018)
Table Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries (2013-2018)
Figure Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales Market Share by Countries in 2017
Table Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Countries (2013-2018)
Table Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2013-2018)
Figure Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries in 2013
Figure Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries in 2017
Figure Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure UAE Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Egypt Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure Nigeria Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Figure South Africa Hormone Refractory Prostate Cancer (HRPCA) Sales and Growth Rate (2013-2018)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales by Type (2013-2018)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Share by Type (2013-2018)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2013-2018)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2013-2018)
Figure Global Chemotherapy Sales Growth (2013-2018)
Figure Global Chemotherapy Price (2013-2018)
Figure Global Hormonal Therapy Sales Growth (2013-2018)
Figure Global Hormonal Therapy Price (2013-2018)
Figure Global Immunotherapy Sales Growth (2013-2018)
Figure Global Immunotherapy Price (2013-2018)
Figure Global Radiation Therapy Sales Growth (2013-2018)
Figure Global Radiation Therapy Price (2013-2018)
Figure Global Surgery Sales Growth (2013-2018)
Figure Global Surgery Price (2013-2018)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales by Application (2013-2018)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Share by Application (2013-2018)
Figure Global Ambulatory Surgical Centers Sales Growth (2013-2018)
Figure Global Specialty Clinics Sales Growth (2013-2018)
Figure Global Hormone Refractory Prostate Cancer (HRPCA) Sales, Revenue and Growth Rate (2018-2023)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Forecast by Regions (2018-2023)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Market Share Forecast by Regions (2018-2023)
Figure North America Sales Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
Figure Europe Sales Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
Figure Asia-Pacific Sales Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
Figure South America Sales Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
Figure Middle East and Africa Sales Hormone Refractory Prostate Cancer (HRPCA) Market Forecast (2018-2023)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Forecast by Type (2018-2023)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Market Share Forecast by Type (2018-2023)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Sales Forecast by Application (2018-2023)
Table Global Hormone Refractory Prostate Cancer (HRPCA) Market Share Forecast by Application (2018-2023)
Table Distributors/Traders/ Dealers List
※본 조사보고서 [세계의 호르몬 불응성 전립선암 (HRPCA) 시장 2019 : 제조사별, 지역별, 종류/용도별, 시장예측] (코드 : GIR-AC0771) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [세계의 호르몬 불응성 전립선암 (HRPCA) 시장 2019 : 제조사별, 지역별, 종류/용도별, 시장예측] 에 대해서 E메일 문의는 여기를 클릭하세요.